895244-45-8

Basic information

• Product Name: methyl 3-(2-chloroethoxy)-4-methoxybenzoate
• Synonyms: methyl 3-(2-chloroethoxy)-4-methoxybenzoate
• CAS NO: 895244-45-8
• Molecular Weight: 244.675
• Mol File: 895244-45-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 3-(2-chloroethoxy)-4-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(2-chloroethoxy)-4-methoxybenzoate(895244-45-8)
• EPA Substance Registry System: methyl 3-(2-chloroethoxy)-4-methoxybenzoate(895244-45-8)

Safety Data

• Hazardous Substances Data: 895244-45-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 1176169-43-9 C₁₀H₁₁ClO₄ 
• 165121-44-8 3-(2-chloroethoxy)-4-methoxybenzaldehyde 
• 621-59-0 isovanillin 
• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 1188906-89-9 methyl 5-(2-chloroethoxy)-4-methoxy-2-nitrobenzoate 
• 1445861-29-9 4-(3'-chloro-4'-fluorophenylamino)-6-[2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)oxethyl]-7-methoxyquinazoline 
• 1456070-09-9 C₂₂H₂₂ClFN₄O₃ 
• 1456070-10-2 C₂₂H₂₂ClFN₄O₂S 
• 1456070-11-3 C₂₂H₂₂ClFN₄O₄S 
• 808793-73-9 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(2-chloroethoxy)quinazoline 
• 1456070-12-4 C₂₀H₂₀ClFN₄O₃ 
• 1456070-13-5 C₂₁H₂₂ClFN₄O₃ 
• 1188906-92-4 1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-chloroethoxy)-7-methoxyquinazolin-4-yloxy)phenyl)urea 
• 1188906-90-2 methyl 2-amino-5-(2-chloroethoxy)-4-methoxybenzoate 
• 1188906-96-8 1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-morpholinoethoxy)quinazolin-4-yloxy)phenyl)urea 

Relevant articles and documents

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors

Aryl phenyl ureas with a 4-quinazolinoxy substituent at the meta-position of the phenyl ring are potent inhibitors of mutant and wild type BRAF kinase. Compound 7 (1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy) phenyl)urea hydrochloride) exhibits good pharmacokinetic properties in rat and mouse and is efficacious in a mouse tumor xenograft model following oral dosing.

QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF

Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.